Relation between Plasma Trough Concentration of Pazopanib and Progression-Free Survival in Metastatic Soft Tissue Sarcoma Patients

Background: Pazopanib (PAZ) is an oral angiogenesis inhibitor approved to treat soft tissue sarcoma (STS) but associated with a large interpatient pharmacokinetic (PK) variability and narrow therapeutic index. We aimed to define the specific threshold of PAZ trough concentration (C_min) as...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Marie-Sophie Minot-This, Pascaline Boudou-Rouquette, Anne Jouinot, Sixtine de Percin, David Balakirouchenane, Nihel Khoudour, Camille Tlemsani, Jonathan Chauvin, Audrey Thomas-Schoemann, François Goldwasser, Benoit Blanchet, Jérôme Alexandre
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	MDPI AG 2022-06-01
Schriftenreihe:	Pharmaceutics
Schlagworte:	Pazopanib pharmacokinetics soft-tissue sarcoma progression-free survival toxicity
Online-Zugang:	https://www.mdpi.com/1999-4923/14/6/1224
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!